Peptide News Digest

#Isomorphic-Labs

2 stories

Industry · View digest

Network Bio Launched Thursday August 20, 2026 With $50 Million in Series A Financing to Build AI Models Trained on Human Biological Data for Drug Discovery, Adding to the Rapidly Expanding AI-Driven Peptide and Biologic Discovery Ecosystem That Also Includes PeptiDream's PDPS Platform (Constrained Cyclic Peptide Focus, Partnerships With Novartis, Merck, Genentech, AbbVie, Eli Lilly), Insilico Medicine's Pharma.AI (31 Developmental Candidates, $2.75 Billion Lilly Deal + $2.5 Billion SK Deal + Takeda Collaboration), Aizen Therapeutics' DaX Foundation Model (August 15 Deal With San Diego Public Biotech Worth Up to $100 Million per Target for Oral Peptide Therapeutics), and Isomorphic Labs (Google DeepMind Spinout With AlphaFold-Derived Structural Modeling); The AI Drug Discovery Category Has Accumulated More Than $8 Billion in Partnership Deal Value Across 2026 to Date

Network Bio launched Thursday August 20, 2026 with $50 million in Series A financing. Company thesis: build AI models trained on human biological data (spanning multi-omics, single-cell sequencing, and functional genomics datasets) for drug discovery across multiple therapeutic areas. The launch adds to the rapidly expanding AI-driven peptide and biologic discovery ecosystem that also includes PeptiDream's PDPS platform (Kawasaki-based, constrained cyclic peptide focus with active partnerships across Novartis, Merck, Genentech/Roche, AbbVie, Bristol Myers Squibb, and Eli Lilly), Insilico Medicine's Pharma.AI (31 developmental candidates on the platform, $2.75 billion Lilly collaboration March 2026, $2.5 billion SK Biopharmaceuticals deal June 2026, Takeda strategic collaboration July 2026), Aizen Therapeutics' DaX foundation model (August 15 deal with San Diego public biotech worth up to $100 million per target for oral peptide therapeutics, non-canonical amino acid chemical space at 10x traditional scale), and Isomorphic Labs (Google DeepMind spinout with AlphaFold-derived structural modeling for target validation and small-molecule design). The AI drug discovery category has accumulated more than $8 billion in partnership deal value across 2026 to date, with peptide-focused platforms capturing a substantial share of the total given the growth of the peptide therapeutic modality across obesity (GLP-1 class), rare disease (setmelanotide, palopegteriparatide, vosoritide, avexitide), and oncology (peptide-drug conjugates, radioligand therapies). Network Bio's Palo Alto location adds to the West Coast AI biotech cluster that also includes Recursion, Insitro, and Isomorphic Labs.

Industry · View digest

Aizen Therapeutics Announced a Multi-Program Collaboration With a San Diego-Based Public Biotech to Design Oral Peptide Therapeutics Using Its DaX Foundation Model, Providing Aizen With Several Million Dollars in Initial Revenue and Up to $100 Million in Milestones for Each Nominated Target Across Immunology and Neurology Indications; The DaX Platform Has Been Trained on Millions of Uniquely Annotated Molecules and Receptors and Explores the Non-Canonical Amino Acid (ncAA) Peptide Chemical Space at 10x the Scale of Traditional ncAA Discovery Methods, Positioning It as One of the More Substantial AI-Driven Peptide Discovery Platforms Alongside PeptiDream's PDPS System, Isomorphic Labs, and Insilico Medicine's Pharma.AI

Aizen Therapeutics announced a multi-program collaboration with a San Diego-based public biotech to design oral peptide therapeutics using its DaX foundation model. Deal terms: several million dollars in initial revenue plus up to $100 million in milestones for each nominated target. The collaboration will develop proof of activity with the DaX platform for well-known disease-relevant targets in immunology and neurology indications, with the potential to expand the roster of targets over time. The DaX platform has been trained on millions of uniquely annotated molecules and receptors and explores the non-canonical amino acid (ncAA) peptide chemical space at 10x the scale of traditional ncAA discovery methods. Non-canonical amino acids extend beyond the standard 20 natural amino acids to include modified building blocks that give peptides properties (metabolic stability, membrane permeability, oral bioavailability) that natural peptides do not have; this is essential for the oral peptide therapeutics that the collaboration targets. DaX positions Aizen as one of the more substantial AI-driven peptide discovery platforms alongside PeptiDream's PDPS system (Kawasaki-based, constrained cyclic peptide focus with active collaborations across Novartis, Merck, Genentech, AbbVie, and Eli Lilly), Isomorphic Labs (Google DeepMind spinout with AlphaFold-derived structural modeling), and Insilico Medicine's Pharma.AI (which has secured over $5 billion in partnership deal value across 2026). The collaboration adds to the growing evidence that AI-designed peptides are becoming a distinct drug discovery category with real deal-flow.